A cleverly titled research note always grabs my attention out of the dozens that clutter my inbox every morning. So, I couldn't pass up this one on Alnylam Pharmaceuticals with the sub-head, "Eighty Percent of Success is Showing Up --Woody Allen."   Read More

The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.    Read More

In Wednesday’s Web Extra the traders talk Deere & Co. Find out if this 'ag' name could grow your portfolio. Also Guy Adami has a biotech trade for you.   Read More

Bristol Myers offered a cool $4.5 billion for ImClone Thursday. Is now the time to play biotech?   Read More

In the last month healthcare has emerged as the best performing sector in the S&P. Are drug makers a cure for your portfolio in this economic downturn?   Read More

In Thursday’s Web Extra the traders talk China – now growing at its slowest pace since 2005. Also Pete Najarian has more fun with Pharma.   Read More

Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!   Read More

The S&P closed 20% below its all-time high set in October, making it the last of the three major U.S. stock indexes to fall into a bear market. What's the "Word on the Street?"   Read More

In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.    Read More

What are the best plays when the market enters bear territory?   Read More